Australia - Inggris - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - abacavir hydrochloride monohydrate,lamivudine -

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.76 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sunset yellow fcf aluminium lake; macrogol 8000; hypromellose; titanium dioxide; magnesium stearate; croscarmellose sodium; microcrystalline cellulose - abacavir and lamivudine combination tablets are a combination of two nucleoside analogues (abacavir and lamivudine). ,abacavir and lamivudine combination tablets are indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - abacavir sulfate, quantity: 702 mg (equivalent: abacavir, qty 600 mg); lamivudine, quantity: 300 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; sunset yellow fcf; polysorbate 80; macrogol 400 - kivexa tablets are a combination of two nucleoside analogues (abacavir and lamivudine). kivexa is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - abacavir sulfate, quantity: 351 mg (equivalent: abacavir, qty 300 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; polysorbate 80; triacetin; iron oxide yellow - ziagen (abacavir) is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and children (see clinical trials). this indication is based on surrogate endpoints in studies up to 48 weeks in duration.

Kenya - Inggris - Pharmacy and Poisons Board

mylan laboratories limited c/o surgilinks ltd mylan laboratories limited r&d center plot no. - abacavir sulfate usp lamivudine usp - tablet - abacavir sulfate usp eq. to abacavir 60mg… - antivirals for systemic use: combinations of

Kenya - Inggris - Pharmacy and Poisons Board

cipla ltd cipla house, peninsula business park, ganpatrao - abacavir sulfate usp and lamivudine usp - dispersible tablet - abacavir sulfate usp equivalent to abacavir – 60… - antivirals for systemic use:

Kenya - Inggris - Pharmacy and Poisons Board

mylan laboratories limited c/o surgilinks ltd mylan laboratories limited r&d centre plot no. - abacavir sulfate usp lamivudine usp zidovudine usp - modified-release tablet - abacavir sulfate usp equivalent to abacavir 300mg… - antivirals for systemic use: combinations of

Kenya - Inggris - Pharmacy and Poisons Board

cipla limited cipla house, peninsula business park, ganpatrao - abacavir tablets usp 300 - tablet - abacavir sulphate usp equivalent to abacavir 300mg - antivirals for systemic use:

Kenya - Inggris - Pharmacy and Poisons Board

mylan laboratories limited c/o surgilinks ltd mylan laboratories limited r&d center plot no. - abacavir sulfate usp - modified-release tablet - abacavir sulfate usp eq. to abacavir 30mg - antivirals for systemic use:

Kenya - Inggris - Pharmacy and Poisons Board

mylan laboratories limited c/o surgilinks ltd r & d centre plot no. 34-a anrich industrial - abacavir sulfate usp - modified-release tablet - abacavir sulfate usp equivalent to abacavir 60 mg - antivirals for systemic use: